Schedule of Fair Value of Contingent Consideration Liability

The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective Contingent Consideration liability:

	Contractual		Fair Value on the
	Value		Merger Date
	(In thousands)
Milestone 1	$	1,500	$	1,340
Milestone 2		3,000		1,830
Milestone 3 ⁽^a)		1,500		770
Royalty 1 ⁽^b)		See(b)		5,980
Royalty 2 ⁽^b)		See(b)		1,210
Total	$	6,000	$	11,130

^(a)	Indicates the maximum payable if the Milestone is achieved.

^(b)	As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.

Business Acquisition [Line Items]

Schedule of Contingent Consideration, Measured at Fair Value

The following tables reflect the activity for the Chronix Contingent Consideration measured at fair value using Level 3 inputs:

	Fair Value
	(In thousands)
Balance at December 31, 2021	$	69,621
Change in estimated fair value		(17,577	)
Balance at September 30, 2022	$	52,044

Balance at December 31, 2022	$	40,292
Change in estimated fair value		(13,867	)
Balance at September 30, 2023	$	26,425